Display Settings:

Format

Send to:

Choose Destination
Clin Rev Allergy Immunol. 2007 Jun;32(3):292-7.

The future of biologic agents in the treatment of Sjögren's syndrome.

Author information

  • 1Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, The Netherlands. j.m.meijer@kchir.umcg.nl

Abstract

The gain in knowledge regarding the cellular mechanisms of T and B lymphocyte activity in the pathogenesis of Sjögren's syndrome (SS) and the current availability of various biological agents (anti-TNF-alpha, IFN- alpha, anti-CD20, and anti-CD22) have resulted in new strategies for therapeutic intervention. In SS, various phase I and II studies have been performed to evaluate these new strategies. Currently, B cell-directed therapies seem to be more promising than T cell-related therapies. However, large, randomized, placebo-controlled clinical trials are needed to confirm the promising results of these early studies. When performing these trials, special attention has to be paid to prevent the occasional occurrence of the severe side effects.

PMID:
17992596
[PubMed - indexed for MEDLINE]
PMCID:
PMC2071970
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Write to the Help Desk